BridgeBio Grants Bayer Exclusive License To Commercialize Acoramidis To Treat ATTR-CM In Europe
4/3 09:11
(RTTNews) - Commercial-stage biopharmaceutical company BridgeBio Pharma, Inc. (BBIO) announced Monday that it has granted German pharmaceutical and life sciences major Bayer (BAYZF.PK, BAYRY.PK, BYR.L) an exclusive license to commercialize acoramidis for patients with transthyret...